1089 related articles for article (PubMed ID: 33128197)
21. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
[TBL] [Abstract][Full Text] [Related]
22. Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients.
Dale M; Sogawa H; Seyedsaadat SM; Wolf DC; Bodin R; Partiula B; Nog R; Latifi R; John D; Veillette G; Diflo T; Nishida S
Transplant Proc; 2021 May; 53(4):1175-1179. PubMed ID: 33888342
[TBL] [Abstract][Full Text] [Related]
23. A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Kheirabadi D; Haddad F; Mousavi-Roknabadi RS; Rezaeisadrabadi M; Dehghan H; Fazlzadeh A
J Med Virol; 2021 May; 93(5):2705-2721. PubMed ID: 33463727
[TBL] [Abstract][Full Text] [Related]
24. Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients.
Demir Önder K; Seremet Keskin A; Berk H; Seyman D; Öztoprak N
Turk J Med Sci; 2021 Dec; 51(6):2835-2849. PubMed ID: 34418000
[TBL] [Abstract][Full Text] [Related]
25. One year update on the COVID-19 pandemic: Where are we now?
Mishra SK; Tripathi T
Acta Trop; 2021 Feb; 214():105778. PubMed ID: 33253656
[TBL] [Abstract][Full Text] [Related]
26. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
27. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
28. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
Ali S; Khalid S; Afridi M; Akhtar S; Khader YS; Akhtar H
JMIR Public Health Surveill; 2021 May; 7(5):e27609. PubMed ID: 34009133
[TBL] [Abstract][Full Text] [Related]
29. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
Kouzy R; Abi Jaoude J; Garcia Garcia CJ; El Alam MB; Taniguchi CM; Ludmir EB
JAMA Netw Open; 2020 Jul; 3(7):e2015100. PubMed ID: 32658285
[TBL] [Abstract][Full Text] [Related]
31. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
[TBL] [Abstract][Full Text] [Related]
32. Antiviral treatment of COVID-19.
Şimşek Yavuz S; Ünal S
Turk J Med Sci; 2020 Apr; 50(SI-1):611-619. PubMed ID: 32293834
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
34. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
[TBL] [Abstract][Full Text] [Related]
35. Remdesivir for the treatment of COVID-19.
Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
[TBL] [Abstract][Full Text] [Related]
36. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
Front Immunol; 2020; 11():569760. PubMed ID: 33362758
[TBL] [Abstract][Full Text] [Related]
38. Clinical management of COVID-19.
Varghese GM; John R; Manesh A; Karthik R; Abraham OC
Indian J Med Res; 2020 May; 151(5):401-410. PubMed ID: 32611911
[TBL] [Abstract][Full Text] [Related]
39. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
Daou F; Abou-Sleymane G; Badro DA; Khanafer N; Tobaiqy M; Al Faraj A
Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33499310
[TBL] [Abstract][Full Text] [Related]
40. What if COVID-19 affects the child: which weapons and how to use them.
Anedda L; Bianchini L; Cuzzolin L; Finco G; Fanos V; Marcialis MA
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(8):3325-3337. PubMed ID: 33928620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
